What is HC Wainwright’s Estimate for BioNTech Q1 Earnings?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for BioNTech in a report issued on Tuesday, March 31st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($2.41) per share for the quarter, down from their previous forecast of ($2.27). HC Wainwright has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2026 earnings at ($2.43) EPS, Q3 2026 earnings at $0.69 EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($4.57) EPS.

A number of other equities research analysts have also issued reports on the company. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday, March 25th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a research note on Tuesday, March 17th. BMO Capital Markets decreased their target price on BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. The Goldman Sachs Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. Finally, Bank of America reaffirmed a “buy” rating and issued a $128.00 price target on shares of BioNTech in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $133.07.

BioNTech Price Performance

BioNTech stock opened at $91.18 on Thursday. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $101.78 and a 200-day moving average price of $101.26. The firm has a market capitalization of $22.92 billion, a PE ratio of -17.40 and a beta of 1.58.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently bought and sold shares of BNTX. Royal Bank of Canada boosted its position in BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of BioNTech during the 1st quarter worth $167,000. Geode Capital Management LLC boosted its position in BioNTech by 2.4% during the second quarter. Geode Capital Management LLC now owns 103,750 shares of the company’s stock valued at $11,046,000 after purchasing an additional 2,402 shares in the last quarter. Russell Investments Group Ltd. boosted its position in BioNTech by 368,800.0% during the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after purchasing an additional 11,064 shares in the last quarter. Finally, Invesco Ltd. grew its stake in BioNTech by 5.6% in the second quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock valued at $72,517,000 after purchasing an additional 35,958 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $130 price objective while raising its Q3 2026 EPS estimate to $0.69 (up from a prior negative forecast), which supports upside expectations for later‑year results. HC Wainwright Lowers BioNTech Price Target
• Positive Sentiment: Balance sheet metrics remain a cushion: very low debt‑to‑equity (~0.01) and high liquidity ratios (quick ratio ~7.49, current ratio ~7.54), which reduces near‑term solvency concerns amid uneven near‑term vaccine revenue. No external link
• Neutral Sentiment: Technical/liquidity context: trading volume was below the stock’s average and the share price remains under both the 50‑ and 200‑day moving averages, suggesting the rally may be tentative without follow‑through buying. No external link
• Negative Sentiment: Pfizer and BioNTech halted recruitment for a large U.S. trial of their updated COVID‑19 vaccine due to low enrollments — a near‑term pipeline setback that reduces the chance of near‑term trial data and future commercial upside from that program. Reuters: Pfizer, BioNTech halt US COVID vaccine study
• Negative Sentiment: HC Wainwright reduced near‑term (Q1, Q2, Q4) and full‑year FY2026 EPS estimates substantially (FY2026 now at –$4.57 vs prior –$3.63), and lowered its price target; those cuts reflect weaker near‑term revenue expectations and likely weighed on sentiment despite the maintained “Buy” rating. HC Wainwright Lowers BioNTech Price Target
• Negative Sentiment: Multiple outlets report the same trial stoppage (Reuters, MSN, Seeking Alpha, ThePharmaLetter), reinforcing the market view that enrollment and demand for updated COVID shots remain suppressed. ThePharmaLetter: COVID vaccine trial scrapped

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.